Astellas Pharma (TSE:4503) Cyclically Adjusted FCF per Share: 円124.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4503 Astellas Pharma Inc TSE:4503
82 GF Score
Price 円2,166.50
GF Value 円2,230.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted FCF per Share?

Astellas Pharma TSE:4503 +0.25% 82 Cyclically Adjusted FCF per Share is 円124.98 as of Mar. 2026. GuruFocus rates TSE:4503 with a GF Score™ of 82/100 and a GF Value™ of 円2,230.31 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Astellas Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was 円102.685. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is 円124.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted FCF Growth Rate was 16.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Astellas Pharma was 10.80% per year. The lowest was 2.70% per year. And the median was 7.70% per year.

As of today (2026-07-27), Astellas Pharma's current stock price is 円2166.50. Astellas Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was 円124.98. Astellas Pharma's Cyclically Adjusted Price-to-FCF of today is 17.33.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Astellas Pharma was 28.14. The lowest was 11.83. And the median was 20.37.


Astellas Pharma  (TSE:4503) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2166.50/124.98
=17.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Astellas Pharma was 28.14. The lowest was 11.83. And the median was 20.37.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Astellas Pharma Cyclically Adjusted FCF per Share Related Terms


Astellas Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted FCF per Share Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.10 101.59 101.42 107.34 124.98

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.34 109.35 117.41 120.72 124.98

TSE:4503 vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted Price-to-FCF falls into.


TSE:4503
82GF Score
Astellas Pharma Inc TSE:4503
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=102.685/112.7000*112.7000
=102.685

Current CPI (Mar. 2026) = 112.7000.

Astellas Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 4.567 98.100 5.247
201609 27.822 98.000 31.995
201612 38.435 98.400 44.021
201703 17.739 98.100 20.379
201706 25.858 98.500 29.586
201709 22.466 98.800 25.627
201712 43.203 99.400 48.984
201803 42.893 99.200 48.730
201806 13.769 99.200 15.643
201809 34.052 99.900 38.415
201812 39.582 99.700 44.743
201903 19.602 99.700 22.158
201906 -1.635 99.800 -1.846
201909 38.348 100.100 43.175
201912 23.684 100.500 26.559
202003 16.347 100.300 18.368
202006 -6.274 99.900 -7.078
202009 44.971 99.900 50.733
202012 50.772 99.300 57.623
202103 33.990 99.900 38.345
202106 10.879 99.500 12.322
202109 38.483 100.100 43.327
202112 31.381 100.100 35.331
202203 17.008 101.100 18.959
202206 16.745 101.800 18.538
202209 38.168 103.100 41.722
202212 28.294 104.100 30.631
202303 47.864 104.400 51.669
202306 -2.316 105.200 -2.481
202309 5.598 106.200 5.941
202312 17.774 106.800 18.756
202403 28.925 107.200 30.409
202406 -6.648 108.200 -6.924
202409 26.807 108.900 27.742
202412 6.567 110.700 6.686
202503 49.633 111.100 50.348
202506 21.750 111.700 21.945
202509 108.304 112.000 108.981
202512 31.929 113.000 31.844
202603 102.685 112.700 102.685

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of 円124.98 mean?
Astellas Pharma (TSE:4503) has a Cyclically Adjusted FCF per Share of 円124.98 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Cyclically Adjusted FCF per Share too high?
Astellas Pharma's current Cyclically Adjusted FCF per Share is 円124.98. Overall, Astellas Pharma has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
Astellas Pharma's Cyclically Adjusted FCF per Share of 円124.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Cyclically Adjusted FCF per Share is 円124.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (TSE:4503) is currently considered Fairly Valued. The stock's GF Value™ is 円2,230.31, compared to a current price of 円2,166.50 — trading 2.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is 円124.98. Astellas Pharma's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Astellas Pharma (TSE:4503), the current Cyclically Adjusted FCF per Share is 円124.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (TSE:4503) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of 円2,166.50 is trading 2.9% below its estimated GF Value™ of 円2,230.31. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for TSE:4503:

  • Cyclically Adjusted FCF per Share: 円124.98
  • GF Value™: 円2,230.31 vs. price of 円2,166.50 (2.9% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the TSE:4503 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
82GF Score

Get the complete analysis for TSE:4503

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,166.50
Price
円2,230.31
GF Value